Key result
In-cath-lab use of GP IIb/IIIa inhibitors, clopidogrel, or both was associated with lower 1-year all-cause mortality (10.4%, 9.0%, and 9.7%, respectively) compared to aspirin alone (15.3%).
Why the study?
Do different antiplatelet regimens (GP IIb/IIIa inhibitors, clopidogrel, or both) added to aspirin reduce all-cause mortality in STEMI patients undergoing primary PCI?
Population
7,193 patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary…
Comparison
In-cath-lab antiplatelet regimens added to 300… vs Aspirin 300 mg alone (n=1,945).
Design
Cohort
Follow-up
1 year
Authors
Loading...
May support adjunctive antiplatelet use in STEMI primary PCI; leaves open causal confirmation by randomized trials.
Cohort (n=7,193)
Yes
Do different antiplatelet regimens (GP IIb/IIIa inhibitors, clopidogrel, or both) added to aspirin reduce all-cause mortality in STEMI patients undergoing primary PCI?
In STEMI patients undergoing primary PCI, adding clopidogrel or GP IIb/IIIa inhibitors to aspirin reduces 1-year mortality, but combining them offers no additional survival benefit over clopidogrel alone.
Witkowski et al. (2009) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=7,193). GP IIb/IIIa inhibitors and/or clopidogrel vs. Aspirin alone was evaluated on All-cause mortality up to 1 year. In-cath-lab use of GP IIb/IIIa inhibitors, clopidogrel, or both was associated with lower 1-year all-cause mortality (10.4%, 9.0%, and 9.7%, respectively) compared to aspirin alone (15.3%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: